At Two Labs, we value partnership. We work hard to make sure our clients view us as an extended part of their team, and not just another vendor. As the pharma market continues to evolve, we are excited to expand our team so that we can provide even more value to our clients as they navigate the path of bringing their products to market.
Two Labs welcomes Micheal Rowe to the team as our new Serialization Services Manager.
As we evaluate the ways that we can best grow and serve emerging pharmaceutical manufacturers, we realize that there is a great need and opportunity to advise clients on the Drug Supply Chain Security Act (DSCSA) regulations and timeline.
Michael comes to Two Labs after working at Cardinal Health for 11 years, most recently serving as the Manager of Operations Technology, where he oversaw Cardinal Health’s track and trace serialization program and advised on DSCSA requirements. His new position at Two Labs will expand the scope of our serialization services to work with more clients as well as downstream with all trading partners.
“There are few people who can understand and advise on the many complexities of DSCSA like Michael can,” said Rich Wartel, Founder and CEO of Two Labs. “His serialization expertise, combined with his experience in project management, sales analytics, operations and customer service in the pharmaceutical manufacturing industry will offer our clients unmatched guidance as they navigate through the DSCSA and bring their new drugs to market. Beyond his skills, he has a true passion for teaching and communicating on the subject, which is extremely valuable in our industry.”
Michael is well-known for his DSCSA expertise and has spoken at several industry conferences and events, including the Healthcare Distribution Alliance’s Traceability Seminar and their Distribution Management Conference, Pharma IQ’s Pharmaceutical Traceability Forum and DSCSA seminars with GS1. He has also participated in several industry task force groups.
Along with helping clients meet the current requirements, Michael is looking ahead to future challenges and opportunities of the DSCSA, including the saleable returns requirement and how to efficiently handle the mass amount of necessary communication and serialization checks; how blockchain’s information storage capabilities could benefit manufacturers and wholesalers; and the analytics possibilities that exist when the kinks have been worked out and the industry is equipped with mass amounts of serial data.
“The opportunities at Two Labs, both for the industry and for me personally, are so exciting,” said Michael. “I am also excited to work alongside so many innovative and intelligent people with the common goal of helping emerging manufacturers bring their medicines to patients who need them.”